My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Eli Lilly (NY:LLY)

1,076.98 +5.34 (+0.50%)

Official Closing Price Updated: 5:00 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Eli Lilly & Co.: Deep Pullback Near 52‑Week Low Tests Strong Fundamentals And Bullish Analyst Targets ↗

August 14, 2025

LLY has given back meaningful ground over recent horizons: the stock is down approximately $103.94 (≈-13.6%) month-to-date and about $119.68 (≈-15.4%) year-to-date.

Via Talk Markets

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India ↗

August 14, 2025

Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market.

Via Benzinga

Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs ↗

August 14, 2025

Via Stocktwits

5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call

August 14, 2025

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, yet the market response was notably negative. Management attributed...

Via StockStory

Topics Earnings

3 Market-Beating Stocks to Keep an Eye On

August 14, 2025

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the...

Via StockStory

Why Eli Lilly Stock Popped Today ↗

August 13, 2025

The GLP-1 weight loss wars have gone global.

Via The Motley Fool

Eli Lilly (LLY) Stock Trades Up, Here Is Why

August 13, 2025

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock...

Via StockStory

Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens ↗

August 13, 2025

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Via Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst ↗

August 13, 2025

William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback.

Via Benzinga

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment ↗

August 13, 2025

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly.

Via Benzinga

Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

August 13, 2025

Via Benzinga

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound ↗

August 13, 2025

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading to millions in improper Medicaid claims.

Via Benzinga

Topics Law Enforcement Lawsuit

The 3 Things That Matter for Viking Therapeutics Now ↗

August 13, 2025

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Via The Motley Fool

Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years ↗

August 12, 2025

Via Benzinga

Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance ↗

August 12, 2025

Texas Attorney General Ken Paxton alleged that Lilly offered illegal incentives to medical providers in Texas designed to steer providers toward prescribing Lilly’s drugs.

Via Stocktwits

Topics Fraud Law Enforcement Lawsuit

Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval ↗

August 12, 2025

Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition.

Via Investor's Business Daily

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now ↗

August 12, 2025

Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases.

Via Benzinga

Topics Lawsuit

UK Government, Eli Lilly Partner To Target Obesity Health Gaps ↗

August 12, 2025

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026.

Via Benzinga

Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock ↗

August 12, 2025

Investors have a tough choice between these two excellent companies.

Via The Motley Fool

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today ↗

August 12, 2025

The biopharmaceutical company has an exciting lead compound in development.

Via The Motley Fool

1 Reason to Buy Eli Lilly (LLY) Stock ↗

August 12, 2025

There's a reason you might want to hold off on buying Lilly stock.

Via The Motley Fool

Topics Government World Trade

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me' ↗

August 12, 2025

Cramer says we are "too negative" on Eli Lilly. "I think they should come back on and talk to me," he adds.

Via Benzinga

If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today ↗

August 12, 2025

Eli Lilly stock plummeted after its recent earnings report, but it's been a long-term winner for investors.

Via The Motley Fool

Novo Nordisk Stock: Buy or Sell? ↗

August 12, 2025

News from a competitor is increasing enthusiasm for Novo Nordisk stock.

Via The Motley Fool

LLY Q2 Deep Dive: Weight Loss Pill Data and Channel Dynamics Spur Investor Uncertainty

August 12, 2025

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 37.6% year on year to $15.56 billion. The company’s full-year...

Via StockStory

Topics World Trade

AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones

August 12, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 4.4% year on year to $174.4 million. Its non-GAAP profit of...

Via StockStory

Topics Economy

Why Eli Lilly Stock Popped Today ↗

August 11, 2025

Eli Lilly stock got cheaper last week. Investors now get a second bite at the delicious GLP-1 apple.

Via The Motley Fool

S&P 500 Earnings Season Concludes with Robust Performance, Signaling Corporate Resilience

August 11, 2025

As the curtain falls on another corporate earnings season, the S&P 500 has delivered a performance that has largely exceeded initial expectations, painting a picture of surprising corporate health...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Unusual volume S&P500 stocks in Monday's session ↗

August 11, 2025

Let's have a look at the S&P500 stocks with an unusual volume in today's session.

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

August 11, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.